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Abstract 
Background. Patients with anxiety disorder diagnoses commonly have more than one anxiety 
diagnosis. While cognitive-behavioral interventions have proven efficacy in treating single 
anxiety disorder diagnoses, there has been little investigation of their efficacy in treating co-
occurring anxiety disorders.  
Aims. To evaluate the efficacy of a transdiagnostic cognitive-behavioral intervention for treating 
co-occurring anxiety disorders. 
Methods. An A-B single case study design (N = 6) was used to evaluate the efficacy of a 12 to 
13 session modular transdiagnostic cognitive-behavioral intervention for treating co-occurring 
anxiety disorders across patients with at least two of the following diagnoses: GAD, Social 
Phobia, Panic Disorder and/or OCD.  
Results. Five of the six participants completed treatment. At post-treatment assessment the five 
treatment completers achieved diagnostic and symptomatic change with three participants 
being diagnosis free. All participants who completed treatment no longer met criteria for any 
DSM-IV-TR Axis-I diagnosis at the three-month follow-up assessment, and demonstrated 
reliable and clinically-significant improvements in symptoms. Across the participants, statistically 
significant improvements from pre- to post-intervention were found on measures of anxiety, 
depression and general well-being, and all improvements were maintained at three-month 
follow-up.  
Conclusions. Results suggest that transdiagnostic cognitive behavioral interventions can be of 
benefit to patients with co-occurring anxiety disorders. 
Keywords:  Anxiety disorder, co-morbid, transdiagnostic, cognitive behavioral treatment, case-
series 
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Case-series evaluating a transdiagnostic cognitive-behavioral treatment for co-occurring 
anxiety disorders. 
1. Introduction 
Cognitive-behavioural therapy (CBT) has demonstrated efficacy in treating the major anxiety 
disorder diagnoses (for a meta-analysis see Hofmann & Smits, 2008). These treatments have 
arisen from first specifying a cognitive-behavioral model explaining the maintenance 
mechanisms and then developing and evaluating diagnosis-specific cognitive-behavioral 
protocols to address the putative maintaining mechanisms (Clark, 2004). Such protocols have 
been developed with reference to patients fitting the diagnostic criteria of a specific anxiety 
disorder, rather than for patients with more than one anxiety disorder. This is a significant 
limitation since 40% - 80% of patients with an anxiety disorder meet criteria for two or more 
anxiety disorders (Brown, Campbell, Lehman, Grisham, & Mancill, 2001; Kessler, Chiu, Delmer, 
& Walters, 2005). There is evidence to suggest that diagnosis-specific protocols are  not being 
delivered in routine care as frequently or optimally as might be ideal (Baker, McFall, & Shoham, 
2009; Stobie, Taylor, Quigley, Ewing & Salkovskis, 2007) and clinicians’ attempts to address the 
high level of co-occurrence amongst disorders may be a partial explanation for this (Shafran et 
al., 2009). Collectively, the results of studies investigating the impact of diagnosis-specific CBT 
on comorbid anxiety disorders would suggest that approximately half of patients will achieve 
remission of co-occurring diagnoses following treatment (Norton et al., 2013). This indicates 
that, despite being beneficial, many patients will continue to present with high levels of co-
occurring anxiety disorder symptoms following diagnosis-specific CBT for their primary difficulty.   
Although a clinically intuitive response to co-occurring anxiety disorders is to administer 
sequential interventions to address the difficulties concurrently or in turn, findings suggest that 
adopting this approach may negatively impact upon efficacy as compared to an equivalent 
duration of a single diagnosis-specific treatments (e.g. Craske et al., 2007).   
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In response to the limitations of single disorder-specific approaches, researchers have 
begun exploring transdiagnostic CBT approaches to anxiety disorders which aim to address co-
occurring anxiety disorders by identifying and reversing common maintaining mechanisms. The 
rationale for this approach is lent weight by the fact that many of the cognitive, behavioral and 
affective processes hypothesized to contribute to the maintenance of anxiety occur across 
diagnostic categories (Harvey, Watkins, Mansell, & Shafran, 2004) and there is evidence to 
suggest that anxiety disorders may have a common core pathology (Clark & Watson, 1991; 
Barlow, Allen, & Choate, 2004).  Indeed, if diagnostic categories represent variations in a 
general syndrome, with common maintaining mechanisms, then treatments addressing the 
commonalities may demonstrate greater efficiency and effectiveness in treating co-occurring 
anxiety disorders than diagnosis-specific approaches (McEvoy & Nathan, 2007).   
A number of attempts to address multiple co-occurring anxiety disorders are underway 
which have reported good clinical outcomes in treating patients’ primary anxiety disorder along 
with significant reductions in symptoms of secondary anxiety disorders. These approaches 
include the ‘unified protocol’ developed by Barlow and colleagues (Barlow et al, 2004; Farchione 
et al., 2012), “transdiagnostic” group CBT protocols (Arch et al., 2013; Norton et al., 2013) and 
internet-delivered transdiagnostic CBT interventions (Johnston, Titov, Andrews, Dear, & 
Spence, 2013).  A number of these interventions incorporate the treatment of mood as well as 
anxiety disorders with the rationale that mood disorders may share a core pathology with 
anxiety disorders  (Barlow et al., 2004) and frequently co-occur (Brown et al., 2001).  However, 
the commonalities in maintenance processes and shared intervention strategies across 
diagnosis-specific interventions for anxiety disorders have arguably yet to be established across 
mood disorders.  A limitation of both these approaches is that they do not incorporate the 
specific interventions developed within evidence-based diagnosis-specific approaches (e.g., 
manipulating self-focused attention in the treatment of social phobia [Clark  et al., 2006] or 
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identifying and modifying cognitive distortions in trauma memories in the treatment of PTSD 
[Ehlers et al., 2003]). Ideally, a transdiagnostic approach would address the common 
maintaining mechanisms across anxiety disorders, whilst also incorporating those specific to a 
given anxiety disorder. Such an approach should therefore aim to achieve a balance between 
adopting a standardized approach across patients, whilst ensuring that the intervention remains 
personalized to the extent where it can address the idiosyncratic presenting difficulties of a 
given individual (Craske, 2012). This approach has been successfully utilized in the treatment of 
eating disorders (Fairburn, Cooper, & Shafran, 2003). Within this approach the intervention is 
guided by a single conceptual model, key transdiagnostic maintenance processes are 
addressed by core treatment modules, and optional modules are delivered according to 
individual need.   
The primary aim of the study was to advance the evidence-base for treating co-occurring 
anxiety disorders by evaluating a treatment protocol for conceptualizing and treating co-
occurring anxiety disorders transdiagnostically, in individuals with two or more anxiety disorders.  
The treatment protocol (Shafran, McManus, Cooper & Clark, 2008) was based on a 
transdiagnostic model of the maintenance of anxiety disorders (McManus & Shafran, 2014) 
shown below (see Figure 1).  The study aimed to evaluate the efficacy of this transdiagnostic 
CBT protocol against whether it was effective in: 
1. ameliorating anxiety disorder diagnoses (DSM-IV-TR Axis-I disorders; APA, 
2000) for patients with co-occurring anxiety disorders 
2. producing clinically significant and reliable reductions in  pathology as measured 
by standardized measures of anxiety, depression and general functioning 
FIGURE 1 INSERTED ABOUT HERE 
2. Method 
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2.1 Design 
The study utilized an A-B case-series methodology (Barlow & Hersen, 1984) with 
stability of participant symptoms assessed weekly for a four-week period prior to beginning 
treatment.  
2.2 Participants 
Following NHS ethical approval participants were recruited by advertising the study in 
the local NHS Psychological Therapies service and on the website of a local CBT center. 
Inclusion criteria were: (i) meeting DSM-IV-TR criteria for at least two anxiety disorders (ii) aged 
18-70 (iii) fluent in English (iv) agreement to keep any psychotropic medication at a stable dose 
for the duration of the study. Exclusion criteria were the presence of: (i) psychotic symptoms (ii) 
active risk of suicide or deliberate self-harm (iii) substance dependence.  
Ten people made contact regarding the study and four were excluded for not meeting 
DSM-IV-TR criteria for at least two anxiety disorders. The remaining six participants were 
included in the study. 
2.3 Measures 
2.3.1 Diagnoses. 
The Structured Clinical Interview for DSM-IV Axis I disorders (SCID-I; First, Spitzer, 
Gibbon, & Benjamin, 1997) was administered by an independent assessor, who was not 
involved in delivering the intervention to establish participant diagnoses. The SCID-I is a 
structured diagnostic interview with demonstrated reliability (κ = 0.65 - 0.83, Lobbestael, 
Leurgans, & Arntz, 2011) for anxiety disorder diagnoses. The reliability of diagnostic 
assessment was established by a second independent assessor re-rating a random selection of 
50% of assessment sessions, with 100% agreement on diagnoses. Assessors also rated the 
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distress and interference caused by the anxiety disorders on a scale from 0 = Not at all to 10 = 
Extremely. Reliability of ratings between assessors was calculated using Intra-class Correlation 
Coefficients (two-way random-effects with absolute agreement on single measures) and was 
ICC = .98 p < .001, for both distress and interference ratings.  
2.3.2 General measures.  
Standard measures were selected based on their use within the evaluation of diagnosis-
specific and transdiagnostic CBT interventions (e.g. Clark et al., 2006; Farichione et al., 2012) 
and their use within NHS outpatient settings.  The measures, which all have good psychometric 
properties, were: The Beck Anxiety Inventory (BAI: Beck, Epstien, Brown, & Steer, 1988), The 
Beck Depression Inventory (BDIII: Beck, Steer, & Brown, 1996), The Clinical Outcomes in 
Routine Evaluation– Outcome Measure (COREOM: Evans et al., 2000).   
2.3.3 Diagnosis-specific measures. 
In addition to the above general measures, standard diagnosis-specific measures were 
used to assess the severity of symptoms for each of the specific anxiety disorders. Each of the 
measures have good psychometric properties and have been used to assess symptomatic 
change across treatment for each relevant disorder. These were: a) The Obsessive-compulsive 
Inventory - Revised (OCI-R: Foa et al., 2002); b) The Social Phobia and Anxiety Inventory 
(SPAI: Turner, Biedel, Dancu, & Stanley, 1989); c) The Panic Disorder Severity Scale- Self-
report (PDSS-SR: Houck, Spiegel, Shear & Rucci, 2002); d) The Penn State Worry 
Questionnaire (PSWQ: Meyer, Miller, Metzger, & Borkovec, 1990). 
2.4 Assessment Schedule and Procedure 
The assessment schedule had six phases: 
1. pre-baseline assessment 
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2. weekly completion of self-report measures during a four-week no-treatment baseline 
period 
3. post-baseline /pre-intervention assessment 
4. completion of self-report assessments at each treatment session  
5. post-intervention assessment  
6. three month follow-up assessment. 
2.5 Treatment Overview 
All treatment sessions were delivered in an individual format by the second author (GC) 
with close supervision from the first and last authors (FM and RS). For an in-depth discussion of 
the treatment protocol see McManus and Shafran (2014).  The intervention components 
comprised of core and optional modules that were based on current empirically validated 
cognitive-behavioural theory and treatment protocols (e.g. NICE, 2011; NICE, 2013). All 
interventions involved the utilization of core modules that were designed to address common 
processes across anxiety disorders (Havery et al., 2004) and common components across 
evidence-based diagnosis-specific approaches. Specifically, core modules focus on the 
conceptual links between the patient’s anxiety disorders and the commonalities between 
diagnosis-specific approaches to anxiety disorders (e.g. misinterpretations of anxiety sensations 
as dangerous, the use of safety seeking behaviors to manage threat) and include: individualized 
transdiagnostic formulation; psychoeducation and information gathering to normalize symptoms; 
addressing avoidance and counter-productive safety strategies; addressing misinterpretations of 
danger (using verbal and behavioural techniques); modifying cognitive biases; and relapse-
prevention planning. Optional modules were also employed selectively according to the nature 
of the difficulties identified within the individual’s formulation. Optional modules address 
processes considered diagnosis-specific or idiosyncratic and include: attenuating low self-
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esteem; problem-solving; addressing self-focused attention; addressing intrusive memories; and 
addressing meta-cognitive beliefs. The intervention is distinct from other transdiagnostic 
approaches such as those of Barlow as (i) it focuses exclusively on the maintenance of anxiety 
disorders, (ii) it has optional modules as well as core modules, (iii) it does not have a specific 
emphasis on interoceptive and situation-based emotion focused exposure or on increasing 
present-focused emotion awareness.  
Participants began treatment at different time points over the course of three months. 
The intervention was intended to be delivered over 12 one-hour treatment sessions according to 
the following schedule: the first six sessions were twice a week, the following four sessions 
weekly, and the last two sessions fortnightly, creating a 12-session, 11-week intervention. 
However, the protocol was designed to meet the idiosyncratic needs of the individual patient 
and so allowed the flexibility of allowing extra sessions if any aspect of the patient’s presenting 
diagnoses was not fully addressed within 12-sessions. Similarly, if it was not possible to 
schedule sessions according to the planned 11-week schedule (due to participants’ availability 
to attend sessions), then treatment duration was extended. The schedule of sessions reflects 
the structure and length of existing evidence-based diagnosis-specific treatments. 
2.6 Data Analysis 
A number of approaches have been suggested for identifying observable and clinically 
meaningful effects within single case research (Borckardt, et al., 2008). This study utilized two 
of the most widely reported  methods, the assessment of the graphical display of change over 
time (Parsonson & Baer, 1992), and the more conservative method of identification of 
statistically reliable and clinically significant change (Jacobson & Truax, 1991). Pairing these 
methods allows the evaluation of whether observed changes are clinically meaningful and 
establishing whether significant change can be attributed to the intervention or to a general 
trend in participant scores. Whether each participant achieved reliable change was assessed by 
calculating a reliable change index (RCI) and clinically significant change (CSC) cut-off for each 
TRANSDIAGNOSTIC CBT FOR CO-OCCURRING ANXIETY DISORDERS       10 
 
measure (Evans, Margison, & Barkham, 1998). CSC cut-off points were calculated under 
criterion C (Evans et al., 1998), which reflects the minimum movement away from the clinical 
mean and towards the mean of a non-clinical population to be confident of a clinically significant 
change – where criterion C falls midway between the two population means.  For measures that 
were completed by four or more participants (BAI, BDI, CORE, SPAI-SP, PSWQ) clinical means 
and SD’s from the current study were used to calculate the RCI and CSC criterion, with 
published clinical means utilized to calculate these criterion for the remaining questionnaires 
(PDSS-SR, OCI-R).  
3. Results 
3.1 Participant Characteristics 
Six Caucasian participants (four female) participated in the case series. All participants 
reported the onset of their anxiety difficulties to be more than five years previously, indicating 
that their difficulties were long-standing and unlikely to be subject to spontaneous remission 
(Bruce et al., 2005). Participants mean age was 34.33 years (SD = 5.72, range 26-41). All 
participants were married apart from P6. All participants had been educated to degree level and 
all were employed apart from P2 who was a student and P5 who was unemployed. At the pre-
intervention assessment participants met criteria for a mean of 3.17 (SD = 0.98) DSM-IV-TR 
Axis I diagnoses, the details of which can be seen in Table 1. None had previously received 
CBT, but three (P2, P3, P4) had received a previous psychological intervention (counseling or 
Jungian psychoanalysis) which had not focused on their anxiety disorders. Participants three 
and four were already taking antidepressant medication prior to joining the trial (Sertraline 
100mg and Fluoxetine 20mg respectively) and remained on this dose throughout their 
participation in the study. One participant (P2) discontinued treatment after six sessions, citing 
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relationship difficulties and work commitments as the reason for being unable to schedule 
further appointments. 
3.2 Stability of Pre-treatment Baseline  
There were no changes in participants’ diagnoses, as assessed by the SCID, across the 
four-week baseline period. Similarly Wilcoxen tests comparing scores from the beginning and 
end of the baseline period showed no significant change on the BAI Z = -0.21, p = .83, BDI Z = -
0.31, p = .75 or CORE Z = -0.52, p = .60 across all participants (N = 6).  
3.3 Post-intervention Outcomes 
3.3.1 Change in diagnoses. 
Table 1 shows participants’ diagnoses, and the distress and interference ratings at pre-
intervention, post-intervention and follow-up assessments.  
INSERT TABLE 1 ABOUT HERE 
 For participants who completed treatment (n = 5) the mean number of diagnoses 
reduced from 3.00 (SD = 1.00) at the pre-intervention assessment to 0.40 (SD = 0.55) at the 
post-intervention assessment and by the 3-month follow-up assessment no participants met 
criteria for any diagnosis. For participants who completed treatment, there were also significant 
reductions in the pre-intervention and follow-up assessor ratings of “distress” (means [SD] 8.60 
[0.89] vs. 2.8 [0.83] z = -2.03, p = 0.04) and “interference” (means [SD] 8.20 [0.84] vs. 2.0 [0.72] 
z = -2.12, p = 0.03). 
3.3.2 Changes standardized measures of anxiety, depression and general 
functioning.  
3.3.2.1 Visual analysis. 
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Participants’ baseline, pre- and post-intervention, and follow-up scores are shown 
graphically in Figures 2 and 3. All participants for whom there is post-intervention data displayed 
generally stable baselines across global and diagnosis-specific measures. Four of these five 
participants (P1, P3, P4, P5) show a pattern of decreasing scores on general and diagnosis 
specific measures across treatment with gains being maintained or improved upon at follow-up. 
The fifth treatment completing participant, P6, shows less clear decreases in general or 
diagnosis-specific measures, despite no longer meeting criteria for any diagnosis by follow-up.  
This may be partially explained by the fact that his pre-intervention questionnaire scores would 
be considered of relatively low clinical severity, making it harder to detect change. P2 (who did 
not complete treatment) demonstrated base-line decreases and post-baseline increases in 
symptoms prior to drop-out.  She attributed this change in symptoms to temporary relief from 
increasing situational pressures (described above) which ultimately led to her discontinuing 
treatment. 
FIGURE 2 & 3 INSERTED ABOUT HERE 
3.3.2.2 Clinically significant change (CSC) and reliable change (RC) 
Individual participants’ scores on self-report measures at the pre-intervention (i.e. post-
baseline), post-intervention and follow-up assessments can be seen in Table 2. P1 achieved 
CSC and RC on the BDI, CORE, SPAI-SP and PSWQ by follow-up. P1 also achieved CSC on 
the BAI and CSC and RC on the OCR-R at the post- intervention assessment but slipped back 
slightly on this measure at follow-up so no longer met criteria for CSC. P2 demonstrated RC and 
CSC during the baseline period only for her scores to return to pre-baseline levels prior to drop-
out. P3 scored below the CSC cut-off at pre-assessment so could not meet CSC criteria for any 
measure. However P3 did show RC on the SPAI-SP at post-intervention and follow up and 
scores on all measures were reduced to non-clinical levels. P4 showed RC and CSC on the 
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BAI, BDI, SPAI-SP, PSWQ and PDSS-SR at follow-up and RC on the CORE (missing the 
criteria for CSC on this measure by less than one point). P5 achieved RC and CSC on the BDI, 
CORE, SPAI-SP, PSWQ and OCI-R at post-intervention and follow-up assessments, and RC on 
the BAI at follow-up. P6 scored below the cut-off for CSC all but one (PSWQ) measure at the 
pre-intervention assessment so could not achieve CSC on most measures, but P6 did achieve 
RC and CSC on the PSWQ by follow-up, and scores on other measures were reduced.  
INSERT TABLE 2 ABOUT HERE 
3. Discussion 
 This study describes a preliminary investigation of a transdiagnostic CBT approach 
to co-occurring anxiety disorders, using a single-case experimental design. Six participants, with 
a range of anxiety disorder diagnoses and severities participated, five of whom completed 
treatment. The intervention was effective in ameliorating participants’ diagnoses, and in 
significantly reducing the distress and impairment associated with the anxiety disorder 
diagnoses, for the five participants that completed treatment. In addition, scores on a range of 
global and diagnosis-specific self-report measures were reduced following the intervention.  
Consistent with trials of diagnosis-specific CBT treatment for anxiety (Hofmann & Smits, 2008) 
treatment gains were largely maintained at three month follow-up. In contrast to the general 
pattern of positive response to the treatment, it is worth noting that one participant (P2) 
discontinued treatment after receiving no benefit. 
 Spontaneous recovery from GAD, social phobia, panic disorder and OCD would not 
be predicted by epidemiological research (Bruce et al., 2005), nor by the fact that the 
participants’ difficulties had been present for a number of years prior to participating in this 
study, or by their demonstrating little change across the four-week baseline period. Additionally 
it is interesting to note that participants showed significant improvements in depression, with 
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three participants achieving reliable and clinically significant change on the BDI (P1, P4, P5), 
and no longer meeting criteria for Major Depressive Disorder at post-intervention or follow-up. It 
is notable that this intervention for anxiety disorders also works for MDD, a finding shared with 
disorder-specific treatments for anxiety which result in significant improvement in depression 
(e.g. Clark et al., 2006). There are a number of possible explanations for this outcome:  the 
treatment may be targeting shared maintaining mechanisms, there may be a generalization of 
skills, or the depression may have been secondary to participants’ anxiety (i.e. associated with 
the functional impairment caused by anxiety symptoms). Whilst it has been argued that there is 
a common core pathology amongst anxiety and mood disorders (e.g. Craske [2012]; Barlow et 
al., [2004]) the transdiagnostic model and protocol was developed to understand and reverse 
those maintenance processes involved in the perception of threat.  An area for future research 
may be whether the impact on co-occurring mood disorders can be better understood and 
whether the transdiagnostic protocol can be updated to be able to address such presentations. 
The findings must be interpreted within the study’s limitations. The generalizability of the 
findings is limited by the small sample and the lack of a control group. The nature of the A-B 
case series methodology means that treatment effects may be attributable to non-specific 
factors (e.g. impact of assessment procedure, non-specific therapeutic effects) and cannot 
necessarily be ascribed to the purported active-ingredients of treatment (Barlow & Hersen, 
1984). Similarly, lack of data regarding the timing and content of previous psychological 
intervention that participants had received means that the potential impact of this on treatment 
outcome is unknown. The lack of a comparison to an alternative evidence-based intervention 
means that it cannot be determined what benefit the transdiagnostic model and protocol 
created, over and above generic or diagnosis-specific CBT interventions. Additionally, whilst the 
assessments and reliability checks were carried out by individuals who were not involved in the 
delivery or supervision of the intervention, it was not possible to blind the assessors to the stage 
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of assessment. Consequently, the possibility of overestimating treatment effects exists.  A 
further consideration in interpreting the results is that the general symptom measures utilised 
(e.g. BAI) may not equitably detect change across anxiety disorder diagnoses (Cox, Cohen, 
Direnfeld & Swinson, 1996). Finally, the treatment being delivered by only one therapist also 
limits generalizability. However, the fact that the intervention was carried out by a relatively 
inexperienced therapist, with patients from NHS referral pathways, suggests that the protocol 
may be able to generalize to outpatient clinical settings and be disseminated to relatively novice 
clinicians.  
Collectively the results provide a provisional indication that the transdiagnostic CBT 
intervention can successfully treat co-occurring anxiety disorders, bringing about significant 
symptomatic change as well as effecting change in diagnostic status, with treatment gains being 
maintained or improved upon in the three months following treatment. Thus the results of this 
study provide provisional validation of a transdiagnostic CBT protocol for treating co-occurring 
anxiety disorder.  
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